This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Analysts Estimate Supernus Pharmaceuticals (SUPN) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Supernus (SUPN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Supernus Pharmaceuticals (SUPN) Q4 Earnings Beat Estimates
by Zacks Equity Research
Supernus (SUPN) delivered earnings and revenue surprises of 8.77% and -6.36%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Can Value Investors Pick Supernus Pharmaceuticals (SUPN) Stock?
by Zacks Equity Research
Is Supernus Pharmaceuticals (SUPN) a great pick from the value investor's perspective right now? Read on to know more.
Supernus Pharmaceuticals (SUPN) Q3 Earnings and Revenues Lag Estimates
by Zacks Equity Research
Supernus (SUPN) delivered earnings and revenue surprises of -8.47% and -6.51%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Supernus Pharmaceuticals (SUPN) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Supernus (SUPN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Can Value Investors Pick Supernus Pharmaceuticals (SUPN)?
by Zacks Equity Research
Let's see if Supernus Pharmaceuticals (SUPN) stock is a good choice for value-oriented investors right now from multiple angles.
Supernus Pharmaceuticals (SUPN) Q2 Earnings Top Estimates
by Zacks Equity Research
Supernus (SUPN) delivered earnings and revenue surprises of 8.93% and -3.70%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
4 Medical Stocks to Consider After Federal Judge Blocks Trump Proposal
by Christopher Vargas
In early May, President Donald Trump announced that he would be requiring Big Pharma to list the prices of their drugs in their TV advertisements.
Supernus Pharmaceuticals (SUPN) Lags Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Supernus (SUPN) delivered earnings and revenue surprises of -22.73% and -18.09%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Supernus Pharmaceuticals (SUPN) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Supernus (SUPN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Supernus' ADHD Candidate Positive in 4th Phase III Study
by Zacks Equity Research
Supernus (SUPN) releases top-line results from the fourth phase III study on SPN-812 for the treatment of attention deficit hyperactivity disorder.
MYL vs. SUPN: Which Stock Is the Better Value Option?
by Zacks Equity Research
MYL vs. SUPN: Which Stock Is the Better Value Option?
Supernus Pharmaceuticals (SUPN) Tops Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Supernus (SUPN) delivered earnings and revenue surprises of 20.93% and 2.40%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Supernus Pharmaceuticals (SUPN) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Supernus (SUPN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Supernus Pharmaceuticals (SUPN): Moving Average Crossover Alert
by Zacks Equity Research
Supernus Pharmaceuticals, Inc. (SUPN) could be a stock to avoid from a technical perspective
New Strong Sell Stocks for October 10th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:
Supernus Pharmaceuticals (SUPN) Surpasses Q2 Earnings Estimates
by Zacks Equity Research
Supernus (SUPN) delivered earnings and revenue surprises of 29.55% and -1.46%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Implied Volatility Surging for Supernus (SUPN) Stock Options
by Zacks Equity Research
Supernus (SUPN) needs investors to pay close attention to the stock based on moves in the options market lately.
Supernus Drops SPN-810's Lower Dose Test in Phase III Trials
by Zacks Equity Research
Supernus (SUPN) decides to stop evaluating the lower dose option of SPN-810 for treatment of impulsive aggression. However, the company will carry on with the study of higher dose arm or placebo.
Supernus Pharmaceuticals (SUPN) Jumps: Stock Rises 6.2%
by Zacks Equity Research
Supernus Pharmaceuticals, Inc. (SUPN) moved big last session, as its shares jumped over 6% on the day.
Stocks Most Likely to Beat Earnings for the Week of December 12th
by Zacks Equity Research
Here are four stocks that are likely to beat earnings for the week of December 12th:
Top Ranked Income Stocks to Buy for November 28th
by Zacks Equity Research
Here are four stocks that are likely to beat earnings for the week of November 28th: